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Abstract
Background: Infliximab is usually administered by two monthly intravenous (iv) infusions, therefore requiring visits
to hospital. Adalimumab is administered by self subcutaneous (sc) injections every other week. Both of these anti-
TNF drugs appear to be equally efficacious in the treatment of Crohn’s Disease and therefore the decision
regarding which drug to choose will depend to some extent on patient choice, which may be based on the mode
of administration.
The aims of this study were to compare preferences in Inflammatory Bowel Disease (IBD) patients for two currently
available anti-TNF agents and the reasons for their choices.
Methods: An anonymous questionnaire was distributed to IBD patients who had attended the Gastroenterology
service (Ulster Hospital, Dundonald, Belfast, N. Ireland. UK) between January 2007 and December 2007. The patients
were asked in a hypothetical situation if the following administering methods of anti-TNF drugs (intravenous or
subcutaneous) were available, which drug route of administration would they choose.
Results: One hundred and twenty-five patients fulfilled the inclusion criteria and were issued questionnaires, of
these 78 questionnaires were returned (62 percent response). The mean age of respondent was 44 years. Of the
total number of respondents, 33 patients (42 percent) preferred infliximab and 19 patients (24 percent) preferred
adalimumab (p = 0.07). Twenty-six patients (33 percent) did not indicate a preference for either biological therapy
and were not included in the final analysis. The commonest reason cited for those who chose infliximab (iv) was: “I
do not like the idea of self-injecting,” (67 percent). For those patients who preferred adalimumab (sc) the
commonest reason cited was: “I prefer the convenience of injecting at home,” (79 percent). Of those patients who
had previously been treated with an anti-TNF therapy (n = 10, all infliximab) six patients stated that they would
prefer infliximab if given the choice in the future (p = 0.75).
Conclusions: There was a trend towards patient preference for infliximab (iv) treatment as opposed to
adalimumab (sc) in patients with IBD. This difference may be due to the frequency of administration, mode of
administration or differing ‘times in the market-place’, as infliximab had been approved for a longer period of time
in Crohn’s disease. Further studies are required in IBD patients to investigate whether patient choice will affect
compliance, patient satisfaction and efficacy of treatment with anti-TNF therapies.
Background
Inflammatory bowel diseases (IBD) are chronic relapsing
and remitting disorders with varying degrees of severity.
The early use of biological therapies, in particular anti-
TNF therapies (e.g. infliximab and adalimumab) can
induce and significantly increase remission rates without
the need for corticosteroids and surgery in Crohn’s dis-
ease [1]. In moderate-to-severe Ulcerative Colitis, inflixi-
mab has been shown to significantly reduce the rate of
colectomy [2]. Furthermore infliximab may alter the nat-
ural history of Crohn’s disease post-operatively by redu-
cing endoscopic and histological recurrence [3].
Adalimumab is a relatively new anti-TNF therapy and is
also licensed for the treatment of Crohn’s disease. It
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appears to be effective in inducing remission in Crohn’s
disease [4] and has been shown to reduce hospitalisa-
tions and surgery at one year [5], with resulting sus-
tained improvements in health-related quality of life [6].
Therefore with the potential exciting benefits of anti-
TNF therapy there may be a further increase in the use
of these drugs in the future management of IBD.
These drugs have contrasting modes of administration
and dosing schedules. Infliximab (5 mg/kg maintenance;
Remicade®, Schering-Plough) is administered by intrave-
nous (iv) infusion usually once every six to eight weeks
in a day-treatment facility by a trained healthcare pro-
fessional, over a period of two hours. Patients are
required to stay for up to one to two hours after an
infusion for clinical observation. Adalimumab (40 mg
maintenance, Humira®, Abbott Laboratories) was
approved for use in Crohn’s Disease in 2007 and in con-
trast to infliximab, is administered by subcutaneous (sc)
injection usually once every two weeks.
These two anti-TNF drugs while appearing to have simi-
lar efficacies, have contrasting modes of administration
and may offer potential opportunities to patients. The
advantages of self-administration may be that patients do
not need to attend clinics at specific times, allowing flex-
ibility of administration. But this will require the patient or
a close family member to be responsible for administra-
tion. In contrast infliximab requires regular attendance at
a day case treatment facility, but the patient and/or family
member have minimal responsibilities for the administra-
tion of the drug. This attendance provides an opportunity
for the patient and family to discuss concerns about their
disease or treatment with either other patients or a health-
care professional.
Shared decision making, in which patients and health
professionals join in both the process and responsibility
for the decisions made, is attracting considerable inter-
est as a strategy by which patients’ preferences can be
employed into management decisions [7]. Where several
treatment options exist which may have different effects
on the patients quality of life, there is a strong argument
to offer patients the choice of agent as their active invol-
vement in decision making may increase the effective-
ness of the treatment [8]. This is supported by The UK
Department of Health Guidance in 2001[9], which
recommends that patients should be fully involved in
the management decisions of ’non life-threatening
diseases’.
It is thought that improved awareness of the factors
that influence patient preferences will facilitate the
patient-doctor communication, discussion and ulti-
mately improve patient management [10]. Hibbard has
stated that patients’ preferences should be considered as
importantly as a ’vital sign’, and therefore should be reg-
ularly monitored and attended to by clinicians [11]. A
previous study which examined the ‘weight’ of patient
preference on final prescribing, showed that 50 percent
of patients wished to leave final medical decisions to the
clinician but 96 percent ultimately wanted to be offered
choices and asked their opinion [12].
Patient preference studies comparing drugs of the
same class but having differing dosing frequencies have
been performed in various disease states including: dia-
betes (e.g. comparing differing modes of insulin delivery)
[13]; gastro-esophageal reflux disease [14]; osteoporosis
[15-19] and irritable bowel syndrome [20]. However
patient preference studies for anti-TNF drugs are lim-
ited and have only previously been reported in the set-
ting of rheumatoid arthritis [21]. No previous studies
have been performed in IBD patients to assess prefer-
ence for drug treatments, and in particular preference
for anti-TNF therapies.
The aims of this study are to compare the preferences
in IBD patients for two currently available anti-TNF
agents in terms of their mode of administration, and the
reasons for their choices.
Methods
The inclusion criteria for this study were IBD patients
who had attended the Ulster Hospital (Dundonald, Bel-
fast, NI. UK) Gastroenterology Service (either as an in-
or out-patient consultation) during the period January
2007 to December 2007. Patients were identified from
the Ulster Hospital Inflammatory Bowel Disease
Database, (Rotherham IBD database, Ferring
Pharmaceuticals).
A questionnaire was devised and contained the follow-
ing questions: age of patient; their principal diagnosis
(Crohn’s, ulcerative colitis, or indeterminate colitis);
whether they have ever required surgery for complica-
tions and if so how many procedures they had under-
gone. The questionnaire also included: the number of
visits to the Gastroenterology Service in the previous 12
months; and what impact IBD has had on (a) lifestyle
and (b) employment. The patients self-reported their list
of medications both currently and previously prescribed
[Appendix 1].
The patients were then asked in a hypothetical sce-
nario as to which route of administration of anti-TNF
therapy that they would prefer if given the choice in the
future. The possible outcomes were as follows: (a) inflix-
imab [iv] in hospital every 8 weeks approximately, (b)
adalimumab [sc] every 2 weeks at home, or (c) no pre-
ference for biological therapy. The patients were asked
for the reasons for their choice of particular administra-
tion route. In addition, patients who had previously
received an anti-TNF therapy were asked whether they
would choose to have the same or alternative route of
administration in the future if indicated.
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Statistical Analyses
The responses were analysed using the Binomial Prob-
ability test (Statistical Package for the Social Sciences
[SPSS], Version 14) to analyse potential differences in
preference for anti-TNF therapies, a p value of < 0.05
was considered statistically significant.
This questionnaire study was approved for use by the
‘Quality and Effectiveness Department’ at the Ulster
Hospital, Dundonald, Belfast.
Results
One hundred and twenty-five patients fulfilled the inclu-
sion criteria and were issued questionnaires, of these 78
questionnaires were returned, (62 percent response).
Please refer to table 1 for: average age of respondent;
diagnoses; the length of course of the disease; the num-
ber of surgeries; and the number of visits to outpatient
department in the previous twelve months.
The medications currently and previously prescribed
were collated. In total 59 patients (75 percent) had pre-
viously or were currently prescribed 5-aminosalicylates
(5-ASA). In total, ten patients (13 percent) had pre-
viously been prescribed biological therapies (n = 10 all
infliximab).
In response to the question, “How much has your life-
style been affected by inflammatory bowel disease?” The
responses were as follows: “Not at all,” (46 percent); “A
moderate influence” (23 percent) and; “A great deal of
influence” (31 percent). In response to the question,
“How much influence has IBD had on your employ-
ment?” The responses were: “Not at all,” (33 percent);
“A moderate influence” (29 percent); and, “A great deal
of influence” (38 percent).
The patients were asked in a hypothetical situation as
to which mode of administration of anti-TNF agent they
would prefer if given the choice. Of the total number of
respondents, 33 patients (42 percent) preferred inflixi-
mab and 19 patients (24 percent) preferred adalimumab
(p = 0.07). Twenty-six patients (33 percent) did not
indicate a preference for either biological therapy; these
patients were not included in the analysis.
The commonest reasons cited for those patients who
chose infliximab were: “I do not like the idea of self-
injecting,” (n = 22, 67 percent); “I prefer to take the drug
less often,” (n = 14, 42 percent); and, “I prefer the conve-
nience of this choice,” (n = 12, 36 percent). The com-
monest reasons cited for those patients who chose
adalimumab were: “I prefer the convenience of injecting
at home,” (n = 15, 79 percent); “No requirement to visit
hospitals regularly between clinic visits,” (n = 12, 63 per-
cent); and “I prefer the less complicated technique of
drug administration,” (n = 10, 53 percent).
Of the patients who had previously or currently
receiving infliximab (i.e. n = 10), six stated that would
prefer infliximab if given the choice in the future. This
difference was not statistically significant (p = 0.75).
Table 1 The number of patients included in study, time from diagnosis (years), requirements for surgery and those
who had attended the Gastroenterology Outpatients in 2007.
Number of respondents (%)
n = 78
Mean age of respondent 44 years
Diagnoses Ulcerative Colitis 40 (51%)
Crohn’s Disease 28 (36%)
Indeterminate colitis 10 (13%)
Time from diagnosis (years) <1 year 1 (2.6%)
1-3 years 19 (24.4%)
4-7 years 24 (30%)
8-10 years 10 (12.8%)
>10 years 24 (30%)
Requirement(s) for surgery Total number of patients who had previous
surgery
18 (23%)
1 operation 9 (47%)
2 operations 1 (6%)
3 operations 2 (12%)
4 or more operations 6 (35%)
No. of patients attending the Gastroenterology
Outpatient Department in previous 12 months
One visit 24 (31%)
two visits 18 (23%)
three or more visits 22 (28%)
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Discussion and Conclusions
In this study nearly twice the number of patients sur-
veyed would prefer to have an intravenous infusion
(two-monthly) as opposed to self-administering a subcu-
taneous injection at home (fortnightly), however this dif-
ference did not reach the pre-specified level of 0.05.
This may be due to the small sample size and the study
may be underpowered as a consequence. A third of
patients did not indicate any preference for either anti-
TNF therapy and therefore we could assume that they
would be satisfied with either mode of administration.
In this study there were no significant differences in
preference for either anti-TNF therapy in those that had
previously received infliximab, although these were a
small number of patients.
If we assume that these two drugs have comparable
efficacy in IBD patients then there are some important
differences between them. These are as follows: (1) inflix-
imab requires intravenous infusion and therefore can
only be given in a hospital setting as opposed to adalimu-
mab; (2) infliximab requires less frequent dosing i.e.
usually every eight weeks as opposed to every two weeks
for adalimumab; and (3) infliximab has been licensed for
a considerably longer period (FDA approved in 1998) for
IBD patients than adalimumab (FDA approved in 2007).
Preference for less frequent drug dosing has been
observed in other comparative studies in patients with
osteoporosis [15-18]. In one study in patients with osteo-
porosis the most important reasons for drug preference
derived from ‘importance ratings’ were the: drug effective-
ness (79 percent of patients ranked it as their number one
priority); time on market (14 percent); dosing procedure
(4 percent) and lastly, dosing frequency (3 percent) [19].
This is interesting as it appears that when preference
for two drugs with similar efficacy are compared in
patients with osteoporosis, the time on market appears
to be an important influencing factor in their rationale.
This may have accounted for the trend in preference for
infliximab in this study as it has been licensed for a
greater time on the market than adalimumab.
In contrast to patients with osteoporosis [19], it
appears that frequency of dosing may be an important
determinant in treatment preference decisions in
patients with IBD. As previously stated nearly twice the
number of patients chose infliximab over adalimumab,
and of these 42 percent of patients cited ’less frequent
injections’ as the reason for their choice.
In this study the dosing procedure appeared to be
important in the treatment decisions in IBD patients as
a large proportion that chose infliximab (67 percent),
stated that they did not like ‘self-injecting administra-
tion’. This is in contrast to osteoporosis patients where
the dosing procedure appears to be less relevant [19].
Patient preference studies for anti-TNF therapies have
only been reported in patients with Rheumatoid arthritis
(RA). The findings from this study are in contrast to
these previous studies which addressed preferences for
anti-TNF therapy in RA patients. In one study signifi-
cantly more patients preferred adalimumab to infliximab
[21]. The reasons patients cited for preferring adalimu-
mab were that it was convenient to administer and
would allow them to regain control over their lives. In
another study, one hundred consecutive RA patients
were surveyed as to which anti-TNF therapy they would
prefer if given the choice. The results were similar in
that most patients preferred the subcutaneous rather
than intravenous route of administration and the major-
ity of patients indicated that they would prefer to
receive treatment at home rather than in hospital [22].
It is unclear why patients with RA and IBD differ in
their preferences for biological therapy. Some possible
explanations may include the following: (1) RA patients
may be more immobile and therefore have greater diffi-
culty in attending hospital and therefore would be hap-
pier to self-administer at home; (2) Adalimumab has
been licensed for a longer period of time in RA, and
these patients may have more experience or knowledge
of its use than IBD patients; and (3) many Rheumatol-
ogy Units have dedicated Rheumatology nurses available
to administer these biological drugs, and to instruct and
counsel patients. This scenario of provision of specialist
nurses is not the reality in many IBD units in the UK as
evidenced by the UK Inflammatory Bowel Disease Audit
in 2006 which highlighted the inadequate provision of
dedicated IBD nurses [23]. Rheumatology patients may
feel that they have better contact with the medical and/
or nursing team if required and therefore may be better
educated and prepared to self-administer anti-TNF
drugs at home.
Another possible explanation in this study for the
trend in preference towards infliximab is that a large
proportion of patients (i.e. 73 percent) have had their
disease for greater than four years, and therefore may
have more knowledge of its use in IBD.
Interestingly a large proportion of IBD patients in this
study, believed that their disease had a ‘moderate’ to ‘a
great deal of influence’ on their lifestyle and employ-
ment. The quality of life issues in inflammatory bowel
disease and disease-related quality of life scoring indexes
are well documented [24,25] and there is evidence of
the beneficial effects of anti-TNF therapy on quality of
life [6]. Disability in inflammatory bowel disease is not
clearly defined except for work-related absences [26].
The majority of these patients have stated that they are
unable to perform normally at work and their disease
affects their lifestyle, implying that they may be
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‘functionally-impaired’. The ability of a patient to be
treated early in their disease course, thereby possibly
preventing future complications may affect their quality
of life and reduce their work-related and other disabil-
ities. Validated measures of disability require further
studies in patients with inflammatory bowel disease and
are currently being addressed by the World Health
Organisation.
Patient-involved decision making with regard to the
route of administration of anti-TNF therapy may
improve compliance and ultimately success of therapy
[8]. It has previously been shown that patients are more
likely to participate in decision making regarding their
medications when they understand the various alterna-
tives [27]. In relation to the potential success of therapy
an advantage of infliximab is that it may be preferable
in those with poor compliance allowing health profes-
sionals to better observe these patients. In contrast ada-
limumab may have the potential advantages of allowing
better patient autonomy and may prove to be a lesser
economic burden on the provision of health care ser-
vices [28].
The limitations of this study were the small number of
patients included and only a small number had pre-
viously received anti-TNF therapies. This may have
accounted for the non-significant differences obtained.
Further studies are needed in IBD patients to deter-
mine whether patient choices affect compliance, satisfac-
tion and efficacy of treatment with anti-TNF therapies.
As the efficacy and safety profile of infliximab and adali-
mumab appear to be similar, the decision regarding
which anti-TNF therapy to use may be determined by
joint physician-patient discussion and ultimately patient
choice.
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